About: Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article by Gert Van Assche et al published 23 September 2011 in Gut

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у вересні 2011 (uk) im September 2011 veröffentlichter wissenschaftlicher Artikel (de) article by Gert Van Assche et al published 23 September 2011 in Gut (en)
publication date	wds:Q57265349-8169FAF3-08F6-4A8B-BC3B-7129AED8AE7E
publication date	2011-09-23 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57265349-71C862D5-3498-4BB8-8004-74414F81C1C4
language of work or name	English
author name string	wds:Q57265349-149563E9-EAD8-4D04-91B4-8BFD36AD6AAF wds:Q57265349-18CD80EA-79D6-4AE8-8CC4-6574D61AD185 wds:Q57265349-282FF3C8-668B-4231-B368-61343E2E9381 wds:Q57265349-51E0B230-31D2-48F6-960E-269C2EA93D07 wds:Q57265349-6EC95C78-49ED-4652-BD37-14A22DBE9BAD wds:Q57265349-8F2F682F-2511-4517-B4E9-523E62BBA32A wds:Q57265349-AC80EA6B-2DD9-4788-8F8F-BFF75661C55D wds:Q57265349-D1817C14-B324-40CD-B162-7767538224E5
author name string	Séverine Vermeire Ann Gils Maja Noman Niels Vande Casteele Vera Ballet Christophe Claessens Evelien Humblet Frederik Gabriels
rdfs:label	Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (en) Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (nl)
skos:prefLabel	Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (en) Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (nl)
name	Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (en) Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (nl)
author	wds:Q57265349-04F8CBA2-E3BF-4DB2-A3CB-FA4022889FAD wds:Q57265349-38D990DB-A95B-40EF-968F-B80F6B8C98FA wds:Q57265349-463B9AE4-C2AD-4757-BB93-A0CC4D5A0012
author	Paul Rutgeerts Gert Van Assche Geert D'Haens
title	wds:Q57265349-36997AF3-9953-4B0A-9218-B81E71668538
title	Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial (en)
page(s)	wds:Q57265349-3998DBF4-DE60-4A12-84EF-A34BD65B9A89
page(s)	229-234
instance of	wds:Q57265349-EC7EC7DF-479A-46AF-A55C-CBE38DBA9C94
instance of	scholarly article
main subject	wds:Q57265349-B789A999-386F-4D8B-A239-5D34319CC25E wds:Q57265349-C8AC25BC-A9E9-4FB5-B721-9E489FB6BF79 wds:Q57265349-D234E97E-3243-497F-BFD4-1853D04459C2
main subject	adalimumab Patients Crohn's disease
PubMed ID	wds:Q57265349-6233D603-1AF9-4E16-9024-A665BF8C67F0
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21948942
PubMed ID	21948942
published in	wds:Q57265349-2D11C17B-CFB7-4464-9D36-6E811A25CEEE
published in	Gut
issue	wds:Q57265349-59C8B55F-F0B3-480D-8D8E-030189321942
volume	wds:Q57265349-59AF4288-B253-4EC6-925F-51C4BF9933CC
issue	2
volume	61
DOI	wds:Q57265349-9BB89B29-EF3F-4F95-9F22-BC10413C74B7
DOI	http://dx.doi.org/10.1136/GUTJNL-2011-300755
DOI	10.1136/GUTJNL-2011-300755
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57265349
is cites work of	Biologic agents for IBD: practical insights Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. Targeting TNF-α for the treatment of inflammatory bowel disease The safety of switching between therapeutic proteins Comparative effectiveness of infliximab and adalimumab for Crohn's disease Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience Safety considerations when using anti-TNFα therapy to treat Crohn's disease Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease IBD in 2011: Advances in IBD management--towards a tailored approach Elevated risk of opportunistic viral infection in patients with Crohn's disease during biological therapies: a meta analysis of randomized controlled trials British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults Donning a new approach to the practice of gastroenterology: perspectives from the COVID-19 pandemic epicenter Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn's Disease: Final Results From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review Substitution with Alternative Anti-TNFα Therapy (SAVANT)-Outcomes of a Crohn's Disease Cohort Undergoing Substitution Therapy with Certolizumab Therapeutic peptides in inflammatory bowel disease Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Comparable outcomes of the consistent use versus switched use of anti- tumor necrosis factor agents in postoperative recurrent Crohn's disease following ileocolonic resection Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Utilisation of anti-TNF levels in a UK tertiary IBD centre. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software